Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Interim Management Statement

6 Nov 2013 07:00

RNS Number : 2823S
Persimmon PLC
06 November 2013
 



 

INTERIM MANAGEMENT STATEMENT

 

WEDNESDAY 6 NOVEMBER 2013

 

 

 

Persimmon plc today releases its third quarter Interim Management Statement which covers the period from 1 July 2013 to 5 November 2013.

 

The improvement in sales activity reported at the time of our half year results on 20 August 2013 has continued. Visitor levels to our sites have been c.20% ahead of the prior year and cancellation rates continue to run at historically low levels at c.16% (2012 : c.20%).

 

Whilst recognising the slower market conditions experienced through the summer of 2012 due to the impact of the Queen's Jubilee celebrations and the London Olympic Games, our weekly private sales rate has been c.45% ahead of the prior year since 1 July 2013. The introduction of the Government sponsored Help to Buy equity loan scheme in April 2013, which is only available to buyers of newly built homes, has proved particularly attractive. We have now sold over 3,000 homes under this scheme.

 

We are fully sold up for the current year and have £650 million forward sales reserved beyond 2013, a 41% increase on the comparable prior year position (2012 : £462 million).

 

The Government accelerated the launch of the second part of the Help to Buy measures introducing Government guaranteed mortgages on 8 October 2013 across the whole of the UK housing market. However, with only a limited number of lenders involved in this second phase so far the impact to date has been muted due to the higher level of interest rates being charged. We anticipate sales supported by these guaranteed mortgages will increase as interest rates begin to reduce with more lenders entering the market over coming weeks and months.

 

We believe mortgages associated with the Help to Buy equity loan scheme will remain the preferred choice for the majority of customers of the housebuilding industry given that interest rates for this product are significantly more competitive than those available with the Government guarantee.

 

We have now successfully opened 65 of the 85 new sites identified for the second half of the year to refresh and maintain our national network of 385 sites. These new sites have delivered encouraging reservation rates and will support further margin expansion in the future as we convert reservations into legal completions. We anticipate the number of sites in our network will increase towards 400 outlets by the end of the year.

 

Selling prices in all our regional markets remain firm. Our focus on offering house types which reflect local customer preferences ensures healthy sales rates are maintained to achieve the best return on capital employed from every site.

 

Operating profits delivered by the Group continue to improve with tight control exercised over build costs and overheads. In the first half of the year underlying operating margins increased by 300 bps over the prior year to 15.1%, achieving our medium term target eighteen months ahead of plan. We are confident of achieving further progress in the second half of the year.

 

A key part of our strategy is to continue to build a robust platform for the further growth of the Group through high quality land investment. Since 1 July 2013, we have acquired c. 6,000 new plots of land, c. 1,300 of which have been converted from our strategic land bank. The successful conversion of our strategic land assets into our active site network remains key to the delivery of our higher level of gross margin and free cash generation. We look forward to the results of the Government's current consultation on the localised housing standards associated with obtaining planning consents. A simplification of the red tape relating to these requirements will undoubtedly enable the industry to deliver an increase in new homes more quickly.

 

In response to the improvement in sales we have increased our build rates across the country. Our robust build programmes and processes are enabling the Group to react swiftly to the increase in sales activity. Output of new home timber frames from our Space4 factory in 2013 is anticipated to increase by c.25% over the prior year. The improvement in build efficiency captured by this modern method of construction is helping us to respond to the improved sales rates we are experiencing whilst also providing further benefits of cost control on site. We have also been encouraged by the support provided by our suppliers and sub-contractors to our increased build requirements and look forward to the further development of these long term relationships as they grow in partnership with Persimmon.

 

Despite the ongoing significant investment in work in progress and land we anticipate an increased level of cash holding by the year end (30 June 2013 : £48.1 million).

 

We will give a further update on progress and trading following the year end on Wednesday 8 January 2014.

 

Jeff Fairburn and Mike Killoran will host a conference call with analysts at 9.00 a.m. today. To participate please dial +44 (0) 20 3003 2666, quoting the conference code "Persimmon".

 

An audiocast of the call will be available on www.corporate.persimmonhomes.com from this afternoon.

 

Further information, please contact:

 

Persimmon plc

Citigate Dewe Rogerson

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Tel: +44 (0)1904 642199

Tel: +44 (0)20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUVONRORAARAA
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.